Time-Limited Therapy with Belatacept in Kidney Transplant Recipients

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients

Introduction: In kidney transplant recipients, belatacept is usually pursued indefinitely after it has been started. In the setting of the belatacept shortage and after having evaluated the benefit–risk ratio, we established a strategy consisting of time-limited belatacept therapy/transient calcineu...

Full description

Bibliographic Details
Main Authors: Thibault Letellier, Delphine Kervella, Abderrahmane Sadek, Christophe Masset, Claire Garandeau, Cynthia Fourgeux, Victor Gourain, Jeremie Poschmann, Gilles Blancho, Simon Ville, on behalf of the Divat Consortium
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Journal of Clinical Medicine
Subjects:
kidney transplantation
belatacept
calcineurin inhibitor
transcriptome
RNAseq
Online Access:https://www.mdpi.com/2077-0383/11/11/3229

Internet

https://www.mdpi.com/2077-0383/11/11/3229

Similar Items